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What is already known.  Empyema is a complication of pneumonia and usually caused by pneumococcal 
infection. Childhood empyema incidence in many countries increased during the 1990s and early 2000s.  
The introduction of routine pneumococcal vaccination in 2006 has reduced pneumonia incidence 
(presumably reflecting reduced pneumococcal disease). 
What this paper adds.  More children were admitted to hospitals in Scotland between 2006 and 2013 
than the period 1981 to 2005. Between 2006 and 2010, after the introduction of routine heptavalent 
pneumococcal vaccination empyema incidence doubled but after 13-valent vaccination was introduced 
in 2010, empyema incidence has fallen modestly.  
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ABSTRACT (word count 221) 
Background.  The incidence of empyema increased dramatically in children during the 1990s and early 
2000s. We investigated the relationship between changes in the incidence of childhood empyema in 
Scotland following the 2006 introduction of routine heptavalent conjugate pneumococcal vaccination 
(PCv-7) and the 2010 introduction of the 13-valent (PCV-13) vaccine. 
Methods. This was a whole population study of Scottish hospital admissions between 1981 and 2013 
using ICD-9 and -10 diagnostic codes for empyema. The number of admissions for pneumonia and croup 
was also captured to give insight into secular trends in admissions with other related and unrelated 
respiratory presentations.  
Results. There were 217 admissions with empyema between 1981 and 2005 (mean incidence 9 
cases/million/year) and 323 between 2006 and 2013 (mean incidence 47 cases/million/year), p<0.001. 
The introduction of conjugate vaccines in 2006 was associated with an overall increase in admissions for 
empyema of 2.0 (95% CI 1.4-2.8) per 100,000 children however the incidence rate ratio for empyema 
admission between 2010-2013 was lower relative to 2006-2009 (0.78 [95% CI 0.63, 0.98]. Secular 
changes in pneumonia, but not croup, were comparable to those for empyema.  
Conclusion. The incidence of empyema in Scottish children initially rose in children aged 1 to 9 years 
after the introduction of routine conjugate pneumococcal vaccination however empyema incidence has 
fallen since 2010 when the 13-valent pneumococcal vaccine was introduced. 
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Empyema is a serious complication of pneumonia in children. A number of studies reported an 
increasing incidence of paediatric empyema during the 1990s and early 2000s
1-6
.  Streptococcus 
pneum niae (pneumococcus) is a common cause of pneumonia and the most common pathogen 
isolated in empyema
7, 8
 but our previous data suggested that changes in the epidemiology of empyema 
occurred at a time when pneumonia incidence was static
 1
.  One explanation for the increasing incidence 
of empyema might be changes in pneumococcal virulence or serotype distribution.   
Routine vaccination beginning in infancy with a 7 valent pneumococcal conjugate vaccine (PCV-7) 
containing antigen against serotypes 4, 6B, 9V, 14, 18C, 19F and 23F was introduced  in the USA in 2000 
and subsequently into the UK paediatric schedule in 2006. In the UK, this programme appears to have 
been effective in reducing the frequency of hospital admissions for pneumonia 
8, 9
. In April 2010, PCV-7 
was superseded by  a 13-valent vaccine (PCV-13) providing coverage for six additional serotypes (1, 3, 5, 
6A, 7F and 19A); these serotypes are responsible for a significant proportion of invasive pneumococcal 
disease in UK children 
2
 and the PCV-13 might therefore be expected to lead to a reduction in the 
incidence of empyema. 
We have previously reported data on the incidence of empyema for the childhood population of 
Scotland from 1981 to 2005 
1
 and here we extend our observations to 2013 to include the period when 
PCV-7 and -13 vaccinations were introduced. Given the dissociation between the relative incidence of 
empyema and pneumonia
1
 we hypothesised that the incidence of empyema might continue to rise 
between 2006 and 2013. 
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Hospital admission data were provided by the Scottish Government Information Services Division (ISD) in 
Edinburgh.  The ISD is part of NHS Scotland and provides health information to researchers and to NHS 
Scotland and the Scottish Government.  Inclusion criteria were children aged up to 14 years admitted 
over the time period 1
st
 January 1981 to 31
st
 December 2013 inclusive with a diagnostic coding for 
empyema in four groups (<one year, one to four, five to nine and ten to 14 years old).  As previously 
1
, 
paediatric admissions for pneumonia and croup were also obtained to allow comparison between 
secular trends in empyema incidence and related and unrelated respiratory conditions. Pneumococcal 
serotype data from children admitted to hospitals in Scotland between 2006 and 2010 were provided by 






, international classification of diseases -09 and -10 were used.  Empyema codes were ICD-
9 510.0, ICD-9 and 466.0 and ICD-10 J86.9 and A156-165. Pneumonia codes were ICD-9 480-486 and ICD-
10 J12-18.  Croup was defined as an ICD-9 code 464.4 or 466.0 or ICD-10 code J05.0 or J20.9. 
Analysis 
Incidence rate for admission was given per million children in the population as previously 
1
. For the 
purposes of examining the impact of pneumococcal vaccine the data were divided into three periods of 
similar length – pre-vaccine (2000-5), PCV-7 era (2006-9), PCV-13 era (2010-13). Relative change in 
admission incidence (Incidence rate ratios) was estimated using standard Poisson methods for 
comparisons between eras.
10
  An interrupted time series analysis was carried out for the period 2000 
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and 2013 to measure the absolute change in admissions associated with the introduction of the 2006 
pneumococcal vaccine to the routine immunization schedule on the incidence of the three conditions. 
There were insufficient empyema data available to perform vaccine specific analyses. Similar techniques 
have been used to assess the impact of vaccination on pneumonia and empyema.
11, 12
 Standard 
statistical software was used (SPSS version 20.0.0 and R version 3.0.1 –nLME & epiR packages) and 





 January 1981 and 31
st
 December 2013 540 children were admitted to hospital in Scotland 
with empyema, 32,996 with pneumonia and 41,885 with croup. The online supplement presents the 
absolute number of admissions for empyema, pneumonia and croup by year 1981-2013. The total 
number of cases for the period 1981 and 2005 are marginally higher compared to our previous report 
1
 , 
reflecting late cases added to the ISD database since 2005.   
Empyema admissions 
There were 217 admissions with empyema between 1981 and 2005 and 223 between 2006 and 2013, 
equivalent to a rise in the mean annual incidence of 11 admissions per million children (SD 9) for 1981 to 
2005 to 47 (SD 14) after 31
st
 December 2005 (figure 1).  Interrupted time series analysis demonstrated an 
increase in empyema admission incidence of 1.97 extra admissions per 100,000 children associated 
between 2000 and 2013 (95% CI 1.39-2.79); age group specific differences were seen, with an increase 
focussed in the 1-4 and 5-9 years age groups (data not presented). Admission incidence for empyema 
across all age groups combined, increased in the PCV-7 period (incidence rate ratio, IRR, 2.14 [95% CI 
1.65, 2.80]). Within age groups, this increase was seen in the 1-4 and 5-9 year old age groups (IRR 2.26 
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[1.52, 3.42] and 2.88 [1.59, 5.47] respectively) but not others (table 1).   There was a fall in admissions 
between 2006 and 2013 (IRR 0.78 [0.63, 0.98]) when all age groups were considered (table 1).  
 
Pneumonia admissions 
Admissions for pneumonia increased in Scotland when PCV-7 was introduced, IRR 1.08 [95% CI 1.03, 
1.13] when all age groups were considered (table 2)  Within age groups admissions in infants fell (IRR 
0.87 [95% CI 0.78, 0.96]), remained static in 1-4 year olds and rose in the 5-9 year olds (IRR 1.18 [95% CI 
1/07, 1.29]) and 10-14 year olds (IRR 1.16 [95% CI 1.02, 1.32]) (table 2). Admissions for pneumonia fell in 
all age groups apart from infants during the PCV-13 period when compared with the PCV-7 period (table 
2).  There was no change in pneumonia admission incidence between2006 and 2013 in the interrupted 
time series analysis 
 
Croup admissions  
Total croup admissions increased in the PCV-7 era (IRR 1.18 [95% CI 1.13, 1.23]) but remained unchanged  
during the PCV-13 era  (table 3).  Croup admission incidence for infants and 1-4 year olds rose during the 
PCV-7 era but did not fall during the PCV-13 era (table 3).  Admission incidence for 10-14 year olds  fell 
during the PCV-13 era compared to the PCV-7 era (table 3). There was no change in croup admission 
incidence between 2000 and 2013 in the interrupted time series analysis.  
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Pneumococcal serotype data 
Pneumococcal serotype data were available in 41 children admitted between 2006 and 2010 (4 from 
blood and the remainder from pleural fluid samples) during which time a total of 223 children were 
admitted.  Molecular testing at the Scottish reference laboratory did not recover a serotype in 21 cases. 
There were six cases of serotype 1, two of serotype 14A, two of serotype 19A, 4 of serotype 3 and four 
cases of serogroup 7A/F. Two non typeable serotypes were recovered (Multi-locus sequence types - 4119 
and 4122).  
DISCUSSION 
The incidence of empyema in children was still rising abruptly in Scotland in 2005 when we published 
our previous study
1
 and the present study demonstrates that this rise continued after  introduction of 
routine pneumococcal vaccination in 2006 but fell after 13-valent vaccination was introduced in 2010.   
Where serotype data were available for the PCV-7 vaccination era, all cases were infected with non PCV-
7 serotypes suggesting that by extrapolation, the 13-valent conjugate vaccines may be effective in 
preventing invasive disease from the serotypes covered.   Non-vaccine serotypes continue to cause 
morbidity in the UK as has been previously reported
2,13
.  Empyema incidence now seems to be falling  
following the introduction of the PCV-13 vaccine (figure 1) but incidence in 2013 remains  considerably 
higher than 2000.  
 
Our results are generally consistent with reports of increasing empyema incidence during the 2000s from 
the UK and other countries. Two studies from the US 
5, 14
 have observed rises in empyema incidence of a 
very similar order as we report here although in the US studies, pneumonia incidence had fallen several 
years before the reduction seen in our population (table 2). Between 1996-2007, Grijalva et al
5
 report a 
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doubling of empyema admissions in these age ranges (to 70 and 103 cases/million children/year for <2 
and 1.4 year olds respectively) in the context of a33% fall in pneumonia admissions in children aged <2 
years and a 24% fall for 2-4 year olds.  Su-Ting et al
14
 report empyema admissions in <5 year olds 
increasing from 38/million/year in 1997 to 76/million/year in 2006; during this period, pneumonia 
admissions fell by 29% for the <2 year age group.  In a two-centre study from Spain, Obando et al
15
 
report a 13-fold increase in the numbers of children admitted with empyema between 1998 and 2006.  
Data from England and Wales also demonstrate a rise in empyema admissions 1997-2006 which was 
highest in the under 5s
9
.  This latter study did however find a 22% fall in empyema admissions for all 
children between 2006 and 2008 which was mostly explained by falling admissions in infants
9
; here we 
report a 22% reduction in incident rate ratio after 2010 (table 1) for all children with the largest fall also 
being seen in infants.  The greatest fall might be expected in infants since this age group will all have had 
the opportunity for vaccination, whereas children born before 2010 will not have received protection of 
13-valent vaccination. 
 
There are a number of mechanisms which might explain changing empyema admissions and these 
include (non-exclusively) changes in referral patterns, pneumonia incidence, exposure to environmental 
factors (e.g. second hand smoke) and antibiotic prescribing.  Changes in admission incidence for croup 
between 2000 and 2013 do indicate changing drivers for referral to hospital with paediatric respiratory 
conditions per se but the changes in incidence for croup and empyema were different and we imagine 
that very few cases of paediatric empyema will be managed in the community. Changes in empyema 
admissions were different to those of pneumonia, suggesting that the mechanism for the changes in 
empyema do not directly reflect changes in pneumonia incidence as we have previously observed
1
.  We 
do not believe that increasing empyema admission incidence is secondary to a reduction in threshold for 
referral or an increase in pneumonia.   
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The 2005 legislation preventing smoking in the workplace and public spaces has been associated with 
reduced childhood asthma admissions in the UK 
16
 but does not appear to have reduced empyema 
incidence, although our study is underpowered to definitively explore this association.  Our study design 
did not include an assessment of changes in antibiotic prescribing in children but primary care 
prescribing of broad spectrum antibiotics in children in the UK rose between 2000 and 2007
17
 , and in 





A further mechanism which might explain changing empyema incidence is “serotype replacement 
disease” where, following the introduction of a vaccine, non-vaccine serotypes become important 
pathogens.  A recent study from England and Wales following introduction of the heptavalent vaccine 
concluded that herd immunity was well established providing uptake was good but also found evidence 
of serotype replacement with non-vaccine organisms 
19
.  In Alaska, non vaccine type organisms were 
responsible for a significant rise in invasive pulmonary infections in a small population of Alaskan 
children 
20
 and in the UK, there has been a rise in serotype 19A invasive disease since the introduction of 
the 13 valent conjugate vaccine 
2
.  What remains to be seen is wheth r in future, empyema incidence 
rises again due to infections with Pneumococcal serotypes not included in the 13-valent.  
 
There are a number of limitations to this study which should be considered when interpreting the 
results.  First, we report admission incidence and not the number of children admitted and a single child 
admitted twice during an empyema illness would count as two admissions and therefore falsely inflate 
the incidence of empyema, but we believe that this is unlikely to be a significant factor.  Secondly, 
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changes in clinical practice following the 2005 publication of guidelines 
21
 may have increased the 
detection rate for empyema; in this scenario, earlier incidence would have been an underestimate 
however this is unlikely to explain the rise in empyema incidence.  Third, we have relied on hospital 
coding for diagnosis and this may not be accurate in every case although in Denmark, ICD-10 coding had 
a positive predictive value of 95% for case note confirmed empyema in 15-39 year olds 
22
.  Fourth, we  
obtained PCR data in less than 20% of cases admitted between 2006 and 2010 and, although missing 
data is likely to be independent of serotype, our serotype results are at best indicative of the actual 
serotype profile.  Finally, although we suggest that there has been a fall in empyema incidence since 
2010, our experience is that there may be some delay between admission and notification to ISD and 
therefore incidence may be underestimated. 
 
In summary, empyema incidence continued to dramatically rise in children following the introduction of 
PCV-7 but has fallen slightly since the PCV-13 vaccine was introduced in 2010.  The absolute numbers of 
admissions with empyema are very small (approximately 50 cases/million in Scotland and North 
America) compared to pneumonia and croup, but empyema remains a serious condition associated with 
significant morbidity.  Case control studies are now required to give insight into why some children with 
pneumonia go on to develop empyema. 
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Table 1.  Incidence rate ratios comparing incidence of empyema in the pre-vaccine, heptavalent (PCV-7) 
and 13-valent (PCV-13) vaccination eras. SE = standard error, CI = confidence interval, *p<0.05 
PCV-7 versus 
pre vaccine era 
Incidence Rate Ratio SE 95 % CI 
All ages 2.14* 1.14 1.65 2.80 
Infants                   1.72  1.51 0.73 4.38 
1-4 yrs 2.26* 1.22 1.52 3.42 
5-9 yrs 2.88* 1.34 1.59 5.47 
10-14 yrs                   1.44 1.30 0.84 2.53 
     
PCV-13 versus 
PCV-7 era 
    
All ages* 0.78 1.12 0.64 0.98 
Infants 0.47 1.54 0.17 1.14 
1-4 yrs 0.92 1.16 0.68 1.26 
5-9 yrs 0.65 1.26 0.40 1.06 
10-14 yrs 0.63 1.33 0.34 1.12 
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Table 2.  Incidence rate ratios comparing incidence of pneumonia in the pre-vaccine, heptavalent (PCV-7) 
and 13-valent (PCV-13) vaccination eras. SE = standard error, CI = confidence interval, *p<0.05 
PCV-7 versus 
pre vaccine era 
Incidence Rate Ratio SE 95% CI 
All ages 1.08* 1.02 1.03 1.13 
Infants 0.87* 1.06 0.78 0.96 
1-4 yrs 1.01 1.03 0.95 1.07 
5-9 yrs 1.18* 1.05 1.07 1.29 
10-14 yrs 1.16* 1.07 1.02 1.32 
     
PCV-13 versus 
PCV-7 era     
All ages 0.93* 1.02 0.89 0.97 
Infants 0.94 1.06 0.84 1.04 
1-4 yrs 0.88* 1.03 0.83 0.93 
5-9 yrs 0.90* 1.05 0.82 0.99 
10-14 yrs 0.98 1.07 0.87 1.11 
 
Page 14 of 18
http://mc.manuscriptcentral.com/adc

































































Table 3.  Incidence rate ratios comparing incidence of croup in the pre-vaccine, heptavalent (PCV-7) and 
13-valent (PCV-13) vaccination eras. SE = standard error, CI = confidence interval, *p<0.05 
PCV-7 versus 
pre vaccine era 
Incidence Rate Ratio SE 95% CI 95 % CI 
All ages 1.18* 1.02 1.13 1.23 
Infants 1.13* 1.05 1.03 1.24 
1-4 yrs 1.11* 1.03 1.06 1.17 
5-9 yrs 1.04 1.06 0.93 1.17 
10-14 yrs 1.24 1.15 0.94 1.65 
     
PCV-13 versus 
PCV-7 era 
    
All ages 1.02 1.02 0.98 1.06 
Infants 1.06 1.04 0.97 1.16 
1-4 yrs 0.96 1.02 0.91 1.00 
5-9 yrs 0.96 1.06 0.86 1.07 
10-14 yrs 0.64* 1.17 0.46 0.87 
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Figure 1.  Incidence of empyema admissions for children in Scotland between 1980 and 2013.  The 
vertical dashed lines correspond with the introduction of the heptavalent pneumococcal vaccination 
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Figure 1.  Incidence of empyema admissions for children in Scotland between 1980 and 2013.  The vertical 
dashed lines correspond with the introduction of the heptavalent pneumococcal vaccination (PCV-7) and 13-
valent (PCV-13).  
190x142mm (300 x 300 DPI)  
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Year Number of empyema 
admissions 
Number of pneumonia 
admissions 
Number of croup 
admissions 
Number of children in 
the population 
1981 4 964 1,079 1098333 
1982 7 1,040 1,008 1070635 
1983 5 974 1,667 1043756 
1984 8 831 1,014 1018845 
1985 11 819 1,335 998068 
1986 2 763 793 979521 
1987 4 907 1,391 964725 
1988 8 880 988 955009 
1989 2 682 1,454 954826 
1990 5 997 919 955908 
1991 7 1,028 1,582 957724 
1992 8 882 1,364 963963 
1993 7 1,022 1,463 968931 
1994 8 1,069 1,542 969615 
1995 5 1,272 1,454 963364 
1996 3 982 1,416 952790 
1997 8 1,016 1,522 946649 
1998 4 1,231 1,253 940477 
1999 11 881 1,180 933380 
2000 13 955 997 919439 
2001 11 1,026 1272 904997 
2002 8 1,062 933 890242 
2003 21 969 1280 877685 
2004 15 970 873 871907 
2005 32 1,222 1501 865091 
2006 55 1,315 1038 856083 
2007 34 1,065 1662 851334 
2008 36 1,060 952 850206 
2009 56 986 1604 850477 
2010 42 983 1120 851621 
2011 47 1,248 1414 854752 
2012 28 1,061 959 853009 
2013 
25 834 1856 852005 
 
Table E1.  Number of children admitted to hospitals in Scotland per year with empyema, pneumonia 
and croup. 
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